These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277 [TBL] [Abstract][Full Text] [Related]
7. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review]. Yu Q; Shi JM; Tao Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Waldschmidt JM; Anand P; Knoechel B; Lohr JG Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150 [TBL] [Abstract][Full Text] [Related]
16. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Landgren O; Lu SX; Hultcrantz M Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154 [TBL] [Abstract][Full Text] [Related]
17. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. Rawstron AC; de Tute RM; Haughton J; Owen RG Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493 [TBL] [Abstract][Full Text] [Related]
18. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Guerrero C; Puig N; Cedena MT; Goicoechea I; Perez C; Garcés JJ; Botta C; Calasanz MJ; Gutierrez NC; Martin-Ramos ML; Oriol A; Rios R; Hernandez MT; Martinez-Martinez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Mosquera-Orgueira A; Gonzalez-Perez MS; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B Clin Cancer Res; 2022 Jun; 28(12):2598-2609. PubMed ID: 35063966 [TBL] [Abstract][Full Text] [Related]
19. Requirements for operational cure in multiple myeloma. Mohty M; Avet-Loiseau H; Harousseau JL Blood; 2021 Oct; 138(16):1406-1411. PubMed ID: 34324647 [TBL] [Abstract][Full Text] [Related]
20. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Suzuki K Int J Hematol; 2020 Apr; 111(4):512-518. PubMed ID: 32125606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]